

Original Research Article

Is previous Covid 19 infection a boon or bane for dengue patient? - A study from a tertiary care hospital in North India

ABSTRACT

Aims: To study the impact of past COVID 19 infection on various hematological parameters and morbidity in patients with active dengue infection by assessing days of hospital stay, platelet transfusion etc.

Study design: Prospective study

Place and Duration of Study: Department of Pathology, Baba Raghav Das Medical college, Goakhpur, India between June, 2022 to November, 2022

Methodology: 189 patients with active dengue infection, proven on Dengue ELISA for IgM detection, were included in this prospective study. Hematological parameters along with demographic profiles and clinicopathological details were recorded for the patients at the time of admission.

Results: The mean age was comparable between the two groups, dengue patients with past history of COVID 19 (Group A) being 26.93 ± 14.27 years and dengue patients with no history of COVID 19 (Group B) being 28.52 ± 17.65 years. Group A patients were found to have higher mean platelet count [68200.00 ± 28153.33] than Group B patients [54181.21 ± 31792.06]. The fatality rate was 2.68% in the Group A patients and 5% in the group B.

Conclusion: Our research indicates that individuals with a history of COVID-19 infection have reduced dengue mortality. However, we cannot presume a causal association between dengue and COVID-19 infection prognosis.

KEYWORDS

Dengue, Covid 19, Platelet count, Vector borne disease

ABBREVIATIONS

Coronavirus disease: COVID-19

World Health Organization: WHO

Dengue virus: DENV

Laboratory Information system: LIS

Real- Time –Polymerase Chain Reaction: RT-PCR

BACKGROUND

Late in 2019, the coronavirus disease (COVID-19) posed one of the deadliest pandemics since the outbreak of the Spanish flu. It wreaked havoc on the healthcare systems of numerous nations, infecting over three hundred million individuals in more than 216 countries; more than 5 million died from the infection or its complications. [1] In January 2019, before the pandemic, the World Health Organization (WHO) announced the Thirteenth General Programme of Work 2019–2023, in which dengue was identified as one of the four major infections posing the greatest hazard to global health. According to global model data, approximately 33 million clinically manifest dengue cases occur annually in India, accounting for one-third of the global dengue burden. [2,3] Thus, the COVID-19 pandemic burdened nations already coping with dengue fever epidemics. The continuous circulation of both viruses presented a significant problem for the healthcare system, which struggled with patient triage and prognosis. The *Aedes aegypti* mosquito transmits the dengue virus (DENV), which is an RNA virus of the flavivirus genus and is transmitted by the flavivirus genus. DENV1–4 are the four serologically and genetically distinct serotypes. Each of the four serotypes is capable of causing infection, and multiple sequential infections are also possible.

[2] Approximately 25% of those infected with DENV have clinical manifestations, with moderate or severe manifestations in a small percentage, resulting in mortality in 0.1–2.5% of all cases, depending on host factors, access to care, secondary infections, etc. [4] Upon comparing the epidemiological reports from the past five years, the circumstance regarding dengue in India becomes clear. The number of dengue cases decreased significantly in 2020 compared to 2019. [5] Even though the pandemic is nearing its conclusion and lockdowns have been lifted, an increasing number of dengue cases and fatalities are being reported in India's urban and rural areas. As covid 19 virus and DENV share similar biochemical and haematological findings, such as leukopenia and thrombocytopenia, there are growing concerns that dengue and COVID-19 epidemics may interact synergistically, with disproportionately increased morbidity and mortality in vulnerable populations, even though few studies indicate that prior DENV immunity may cross-protect against covid 19 infection and death, despite the fact that dengue virus and SARS-CoV-2 are from different. [6] In India, where dengue is endemic, we sought to determine whether a previous infection with Covid 19 influences the morbidity or mortality of dengue infections. According to our knowledge, this is the first study of its kind conducted in India.

AIM: To study the hematological parameters in patients with active dengue infection and its correlation with past history of Covid 19 infection

OBJECTIVES: To study the effect of past covid 19 infection on various hematological parameters in patients with active dengue infection

To study the impact of past covid 19 infection on morbidity in patients with active dengue infection by assessing days of hospital stay, platelet transfusion etc.

MATERIAL AND METHODS

This prospective study was conducted in the Department of Pathology at the Baba Raghav Das Medical College in Gorakhpur. A total of 189 patients were include in our study. Patients of all ages and gender with active dengue infection, as determined by Dengue ELISA for IgM detection, who presented to the outpatient or inpatient wards of the Department of Medicine

at Baba Raghav Das Medical College, Gorakhpur in the months of July-November 2022, were included in the study. The Ethics Committees waived the subjects' written and verbal informed consent. Blood collection for various hematological parameters was collected by the treating clinician as per the standard protocol and submitted to the Chemical Pathology Laboratory, Department of Pathology, Baba Raghav Das Medical College, Gorakhpur, for complete blood counts. Our hospital's Laboratory Information system (LIS) was used to record the patient's complete blood count parameters and demographic profile. Other clinical information (history of SARS-CoV-2 Qualitative Real-Time Polymerase Chain Reaction (RT-PCR) confirmed covid-19, days of hospital admission or total days of bed rest if treated at home for dengue infection, need for platelet transfusion, history of bleeding diathesis, and overall survival) was collected via telephone. All clinicopathological information was recorded for each case in an Excel spreadsheet. Serology testing was conducted using the Anti-DENV IgM reagent (Euroimmun®, Germany). The technique is based on indirect ELISA, where microplates are coated with a mixture of purified viral antigens and probed with the patient's serum.

Statistical Analysis:

The data obtained from the study were subjected to statistical analysis using SPSS version 26.0 for further evaluation at the significance level of p-value=0.05. The data were presented as Mean \pm standard deviation for continuous variables and frequency for categorical variables. For categorical data, Chi square statistical analysis was done, and for continuous data student's t-test was performed.

RESULTS

A total of 189 patients with active dengue infection were included in our study. The mean age was comparable between the two groups, dengue patients with past history of COVID 19 (Group A) being 26.93 ± 14.27 years and dengue patients with no history of COVID 19 (Group B) being 28.52 ± 17.65 years. 78.8% (149/189) of patients with active dengue infection had no previous history of Covid 19 infection. Females comprised 44.97% of the Group B and 45.00% of the group A. Group A were found to have higher mean platelet count [68200.00 ± 28153.33] than Group B patients [54181.21 ± 31792.06]. In both groups, most patients were vaccinated, but there was no discernible difference in vaccination status. Group A patients had substantially shorter hospital stays, averaging 0.38 ± 0.83 days versus 3.21 ± 3.24 days for Group B patients [Figure-1]. In addition, Group A patients received a substantial reduction in platelet transfusions. The fatality rate was though lower (2.68%) in Group B and 5% in the Group A, yet it was statistically not significant. [Table-1, Figure-2] The mean hemoglobin levels of patients with and without a history of COVID were 11.65 ± 1.58 and 11.74 ± 2.33 , respectively. Comparable levels of neutrophils and total leukocytes were observed between the two groups. However, Group A group had substantially lower lymphocyte levels, with a mean of 17.28 ± 8.27 compared to 24.31 ± 9.45 in the control group. Group A had substantially lower monocyte levels, with a mean of 6.13 ± 1.71 compared to 7.94 ± 1.44 for those without a COVID history. [Table-2]

DISCUSSION

The COVID-19 pandemic took world's healthcare systems by surprise and put enormous pressure on the frequently overburdened medical health facilities including those in India. As referenced by Brady o. et al. [7], the 100 million annual cases of dengue already necessitate a huge part of medical resources and exerts a critical toll on health care system in dengue endemic countries like India and many African countries, with the COVID-19 pandemic further complicating the scenario. The overlapping incidence of COVID-19 and dengue fever

poses difficulties in timely patient diagnosis, treatment and disease prevention. Nevertheless, the direct clinical and pathological consequences of SARS-CoV-2 and dengue virus co-infection have not been fully understood at this point. Based on our observation, dengue patients with previous history of COVID-19 infection had a higher mean platelet count, shorter hospital stay, and received fewer platelet transfusions compared to dengue patients with no history of prior COVID-19 infection.

Two previous studies have found evidence of a similar association. First, an ecological analysis showed a negative correlation between COVID-19 cases and deaths during the first pandemic wave in Brazil and the number of clinical dengue cases recorded at the municipal level [8]. Second, self-reported prior dengue was associated with reduced mortality in hospitalized COVID-19 patients [9].

On the contrary, another study reported that COVID-19 and dengue co-infection had worse outcomes regarding mortality rates, ICU admission, and prolonged hospital stay. Thus, wise decision-management approaches should be adequately offered to these patients to enhance their outcomes. [1]

Notably, regions with higher dengue prevalence had fewer COVID-19 cases and lower COVID-19-related mortality which was also true in our study as we found that most of the patients with active dengue infection (78.8%) had no history of Covid 19 infection in the past [8,9]. These findings suggest that dengue may provide some immunological protection against SARS-CoV-2 infection which also correlates with the findings of our study. In accordance with this assumption, false-positive COVID-19 test results have been reported in dengue patients and false-positive IgM/IgG serological assays for SARS-CoV-2 have been reported in pre-epidemic samples of individuals with antibody-positive dengue. [10-12] Overall, these reports imply that the two diseases share an immune response. COVID-19 patients with active dengue virus infection exhibited reduced circulating lymphocyte and monocyte counts, with lymphocytopenia previously described in patients co-infected with SARS-CoV-2 and dengue virus which is similar to what we found in our study that patients with active dengue infection with past history of COVID 19 had significantly lower levels of lymphocytes and monocytes when compared to dengue patients with no past history of COVID 19. [13]

Cross-reactive antibodies could either neutralize the infection or increase the risk of disease due to antibody-dependent enhancement. [10] This might explain our finding of increased fatality rate (5%) in Group B patients when compared to Group A (2.68%). The main finding of the present study was a decreased morbidity and need of platelet transfusion among patients with active dengue infection with past history of COVID-19. In order to expedite appropriate patient diagnosis and management, our observations ought to be expanded, replicated by others, and utilized by health managers as well as the government to enhance dengue control and COVID-19 control. In order to support control measures and policies to combat dengue and other epidemics while implementing preventive measures against COVID-19 pandemics, the current syndemic scenario—which is not limited to COVID-19 and dengue fever—exhorts governments and health professionals to intensify research.

CONCLUSION

Our research indicates that patients with a prior history of COVID-19 infection have reduced dengue mortality. Patients with previous COVID-19 infections had higher platelet counts, shorter hospital stays, and fewer platelet transfusions than patients with no history of COVID 19 infection. However, the lower lymphocyte and monocyte levels in COVID-positive patients suggest a potential impact of COVID-19 on immune function. However, we cannot presume a causal association between dengue and COVID-19 infection prognosis. Further

studies are required to compare dengue virus exposure and COVID-19 outcomes to clarify the relationship between these two viruses and related immunity.

TABLE-1: Demographics of the enrolled patients in both groups

DEMOGRAPHIC PARAMETERS of DENGUE PATIENTS	COVID HISTORY				P-VALUE
	NO (GROUP B)		YES (GROUP A)		
	N	%	N	%	
AGE (YRS)					
MEAN±SD	28.52	17.65	26.93	14.27	t=0.4635 p=0.6436
GENDER					
FEMALE	67	44.97%	18	45.00%	X=1.435 p=0.9970
MALE	82	55.03%	22	55.00%	
PLATELETS					
MEAN±SD	54181.21	31792.06	68200.00	28153.33	t=2.534 p=0.0261*
VACCINATION					
NO	34	22.82%	14	35.00%	X=2.470 p=0.1161
YES	115	77.18	26	65.00%	
NO. OF HOSPITAL DAY					
MEAN±SD	3.21	3.24	0.38	0.83	t=5.466 p<0.0001*
UNITS PLATELETS TRANSFUSION					
MEAN±SD	1.52	2.27	0.10	0.44	t=3.929 p=0.0001*
OUTCOME					
ALIVE	145	97.32%	38	95.00%	X=0.4426 p=0.5059
DEAD	4	2.68%	2	5.00%	

TABLE-2: Haematological parameters of the enrolled patients in both groups

HEMATOLOGICAL PARAMETERS of DENGUE PATIENTS	COVID HISTORY				P-VALUE
	NO (GROUP B)		YES (GROUP A)		
	MEAN	SD	MEAN	SD	
HB (%)	11.74	2.33	11.65	1.58	t=0.2303 p=0.8181
TLC (Cells/cumm)	11804.03	5909.95	10727.75	1745.90	t=1.137 p=0.2572
NEUTROPHILS (%)	77.16	11.54	77.80	8.71	t=0.3264 p=0.7445
LYMPHOCYTES (%)	24.31	9.45	17.28	8.27	t=4.283 p<0.0001*
MONOCYTES (%)	7.94	1.44	6.13	1.71	t=6.775 p<0.0001*




FIGURE-1: Mean Hospital Stay of the enrolled patients in both groups (1= Group B, 2 = Group A)




FIGURE-2: Outcome of the enrolled patients in both groups (No= Group B, Yes = Group A)

REFERENCES

1. El- Qushayri AE, Kamel AM, Reda A, Ghozy S. Does dengue and COVID- 19 co- infection have worse outcomes? A systematic review of current evidence. *Reviews in Medical Virology*. 2022 Sep;32(5):e2339.
2. Shet A, Kang G. Dengue in India: towards a better understanding of priorities and progress. *International Journal of Infectious Diseases*. 2019 Jul 1;84:S1-3.
3. World Health Organization. *Dengue guidelines for diagnosis, treatment, prevention and control: new edition*. World Health Organization; 2009.
4. Simmons CP, Farrar JJ, van Vinh Chau N, Wills B. Dengue. *New England Journal of Medicine*. 2012 Apr 12;366(15):1423-32.
5. Phadke R, Mohan A, Çavdaroğlu S, Dapke K, dos Santos Costa AC, Riaz MM, et al. Dengue amidst COVID- 19 in India: the mystery of plummeting cases. *Journal of medical virology*. 2021 Jul;93(7):4120.
6. Nicolete VC, Rodrigues PT, Johansen IC, Corder RM, Tonini J, Cardoso MA, et al. Interacting epidemics in Amazonian Brazil: Prior dengue infection associated with increased coronavirus disease 2019 (COVID-19) risk in a population-based cohort study. *Clinical Infectious Diseases*. 2021 Dec 1;73(11):2045-54.
7. Brady O, Wilder-Smith A. What is the impact of lockdowns on dengue?. *Current infectious disease reports*. 2021 Feb;23:1-8
8. Nicoletis MA, Raimundo RL, Peixoto PS, de Andreazzi CS. How super-spreader cities, highways, hospital bed availability, and dengue fever influenced the COVID-19 epidemic in Brazil. *MedRxiv*. 2020 Sep 21:2020-09.].
9. Silvestre OM, Costa LR, Lopes BV, Barbosa MR, Botelho KK, Albuquerque KL, Souza AG, Coelho LA, de Oliveira AJ, Barantini CB, Neves SA. Previous dengue infection and mortality in coronavirus disease 2019 (COVID-19). *Clinical Infectious*

Diseases. 2021 Sep 1;73(5):e1219-21.

10. Nath H, Mallick A, Roy S, Sukla S, Basu K, De A, Biswas S. Dengue antibodies can cross-react with SARS-CoV-2 and vice versa-Antibody detection kits can give false-positive results for both viruses in regions where both COVID-19 and Dengue co-exist. *MedRxiv*. 2020 Jul 6:2020-07.
11. Yan G, Lee CK, Lam LT, Yan B, Chua YX, Lim AY, Phang KF, Kew GS, Teng H, Ngai CH, Lin L. Covert COVID-19 and false-positive dengue serology in Singapore. *The Lancet Infectious Diseases*. 2020 May 1;20(5):536.
12. Lustig Y, Keler S, Kolodny R, Ben-Tal N, Atias-Varon D, Shlush E, Gerlic M, Munitz A, Doolman R, Asraf K, Shlush LI. Potential antigenic cross-reactivity between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and dengue viruses. *Clinical infectious diseases*. 2021 Oct 1;73(7):e2444-9.
13. Saddique A, Rana MS, Alam MM, Ikram A, Usman M, Salman M, Faryal R, Massab U, Bokhari H, Mian MS, Israr A. Emergence of co-infection of COVID-19 and dengue: a serious public health threat. *Journal of Infection*. 2020 Dec 1;81(6):e16-8.

UNDER PEER REVIEW